# Moderna

Type: Company (MRNA)

Source: GetYourBrief — https://getyourbrief.com/entity/moderna
Canonical HTML page: https://getyourbrief.com/entity/moderna

## Timeline

- **2026-Q4**: Anticipated PDUFA — Expected deadline for the FDA's final approval decision.
- **2026-08-05**: Moderna flu vaccine PDUFA date — FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
- **2026-08-05**: FDA final decision deadline — The agency must decide whether to approve the first mRNA-based influenza vaccine, with major implications for the platform’s future.
- **2026-08-05**: FDA Decision Deadline — The agency faces a deadline to approve or reject the vaccine.
- **2026-08-05**: FDA Approval of mRNA-1010 — The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+.
- **2026-06**: Advisory panel recommends approval — The FDA’s Vaccines and Related Biological Products Advisory Committee votes to recommend the mRNA flu shot for licensure.
- **2026-06**: Advisory Panel Recommends Approval — An FDA advisory panel votes in favor of approving the vaccine.
- **2026-03-16**: Court Ruling — Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul.
- **2026-03**: Settlement Reached — Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
- **2026-03-01**: Legal Challenge — The AAP and ACP file suit in Massachusetts federal court to block the changes.
- **2026-02-19**: Thursday Pre-Market — Key reports from Moderna, Newmont, Keurig Dr Pepper, Cheniere Energy, and Viatris.
- **2026-02-18**: FDA U-Turn — FDA agrees to review the application after resolving the public dispute.
- **2026-02-18**: FDA U-Turn — Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
- **2026-02-18**: Regulatory Reversal — FDA agrees to review the application after Moderna addresses concerns.
- **2026-02-18**: Regulatory U-Turn — The FDA officially agrees to consider the application after resolving the internal and public dispute.

## Recent coverage (20 stories, network-wide)

### Healthcare +2.9% to Record, S&P +0.21% as Yields Ease
2026-08-20 00:48:31 · Sector: finance · Sentiment: Strongly positive · Impact: 8/10 · Sources: 4

For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
Full story: https://getfinancebrief.com/story/finance-markets-healthcare-record-yields-ease

### Moderna 177% Surge Lifts S&P 500 Healthcare Sector 2.9% to Record
2026-08-20 00:37:19 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 4

Moderna's mRNA cancer therapy readout sent its shares up as much as 177%, driving a 2.9% record gain in the S&P 500 healthcare sector amid easing Treasury yields. The rally lifted peers including Merck, BioNTech and Novavax, but macro rate worries persist.
Full story: https://gethealthbrief.com/story/moderna-177-pct-healthcare-sector-record

### 5 Value Stocks to Watch: MRNA, QQQ, Intel, Nebius, SpaceX
2026-08-19 21:41:52 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

MarketBeat's August 19 high-volume value screen names Moderna, QQQ, Intel, Nebius, and SpaceX, while a large-cap screen adds SanDisk and Micron. The list highlights where dollar volume concentrated, but classifications include an ETF and a private company, so investors should validate the data before acting.
Full story: https://getfinancebrief.com/story/value-stocks-aug-19-marketbeat-mrna-intc-nbis

### Moderna Leads 2 MarketBeat Watchlists Among 5 Value Stocks
2026-08-19 21:41:40 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moderna appears on both MarketBeat's value and large-cap high-volume screens on August 19, underscoring unusual liquidity and renewed biotech interest despite a post-COVID valuation reset. The mRNA pipeline spans respiratory, latent, and public health vaccines, setting up multiple clinical catalysts.
Full story: https://getbiobrief.com/story/moderna-marketbeat-value-bio-aug-2026

### Coinbase Jumps 11.2% on White House Crypto Push, Bitcoin Eyes $65K
2026-08-19 19:00:01 · Sector: crypto · Sentiment: Positive · Impact: 6/10 · Sources: 2

Coinbase surged 11.2% on August 19, 2026, after CEO Brian Armstrong prepared to meet President Trump and Bitcoin rebounded toward $65,000. The CLARITY Act remains stuck in the Senate, leaving SEC and CFTC rulemaking as the near-term path. For crypto investors, this is a leveraged policy-plus-BTC-beta event.
Full story: https://getcryptobrief.com/story/coinbase-11-2-white-house-crypto-bitcoin-65k

### First mRNA Flu Shot Shows 26.6% Efficacy Boost for Adults 50+
2026-08-06 21:00:40 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

FDA approval of Moderna's mRNA flu vaccine, with a 26.6% relative efficacy improvement over standard shots, signals a shift in seasonal flu prevention strategies for healthcare systems treating older adults.
Full story: https://gethealthbrief.com/story/mrna-flu-vaccine-fda-approval-26-percent-efficacy

### Moderna's mRNA-1010 Approved with 27.4% Efficacy Lead in 65+ Population
2026-08-06 21:00:31 · Sector: bio · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza.
Full story: https://getbiobrief.com/story/moderna-mrna-1010-fda-approval-27-4-percent-efficacy

### Moderna’s mFLUSIVA mRNA Flu Vaccine Wins FDA Nod: 40,000-Patient Trial Suggests Superiority
2026-08-06 20:24:09 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 3

The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Full story: https://getbiobrief.com/story/moderna-mrna-flu-vaccine-approval-fda

### Moderna's mRNA Flu Shot: FDA Decision by Aug 5 Could End 6-Month Regulatory Ordeal
2026-08-01 15:39:40 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 6

After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Full story: https://getbiobrief.com/story/moderna-mrna-flu-shot-fda-decision-aug-5

### FDA's Aug. 5 decision on first mRNA flu shot could reshape $5B flu market
2026-08-01 14:59:02 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 3

The FDA’s imminent decision on Moderna’s mRNA flu vaccine carries high stakes for healthcare providers and the vaccine industry. While an advisory panel backed approval, political skepticism from HHS Secretary RFK Jr. and a prior agency reversal add uncertainty. The ruling could either accelerate or stall mRNA’s expansion beyond COVID-19.
Full story: https://gethealthbrief.com/story/fda-mrna-flu-shot-health-regulation

### Axsome Revenue Doubles to $617M; 3 Biotechs Returned 230% vs. S&P 9% in H1
2026-07-07 06:57:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Full story: https://getfinancebrief.com/story/biotech-beats-sp500-financial-analysis

### Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
2026-07-07 06:57:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Full story: https://getbiobrief.com/story/biotech-outperform-moderna-pdufa-revolution-axsome

### Federal Court Halts RFK Jr.’s Vaccine Policy Shift Amid Public Health Concerns
2026-03-21 00:47:44 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 6

A federal judge has issued a temporary injunction against the vaccine policy agenda proposed by Robert F. Kennedy Jr., citing potential risks to public health infrastructure. While the ruling provides a reprieve for existing immunization standards, experts warn that the ongoing legal and political battle could further erode public confidence in scientific institutions.
Full story: https://gethealthbrief.com/story/federal-judge-blocks-rfk-jr-vaccine-agenda

### Federal Judge Halts RFK Jr.’s Sweeping Vaccine Policy Overhaul
2026-03-17 00:32:23 · Sector: bio · Sentiment: Neutral · Impact: 8/10 · Sources: 2

A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws.
Full story: https://getbiobrief.com/story/judge-blocks-rfk-jr-vaccine-overhaul

### CDC Data Reveals Suboptimal Flu Vaccine Efficacy for 2025-2026 Season
2026-03-14 23:48:17 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
Full story: https://getbiobrief.com/story/flu-vaccine-efficacy-decline-us-officials

### US Flu Vaccine Effectiveness Drops Below Historical Averages for 2025-26 Season
2026-03-14 23:47:43 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Full story: https://gethealthbrief.com/story/flu-vaccine-effectiveness-decline-2026

### Egg Prices Plunge as Avian Flu Recedes, Shifting Focus to Vaccine R&D
2026-03-14 17:01:49 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Full story: https://getbiobrief.com/story/egg-prices-avian-flu-biotech-impact

### Post-Earnings Quant Ratings Reveal Sharp Divide in Healthcare Performance
2026-03-14 15:19:30 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Following the latest earnings cycle, Seeking Alpha's quantitative analysis identifies a significant performance gap between biopharma innovators and retail pharmacy giants. While Incyte and UnitedHealth lead with near-perfect scores, Walgreens and Moderna have fallen into 'Strong Sell' territory.
Full story: https://gethealthbrief.com/story/healthcare-quant-ratings-earnings-2026

### Wix and PAR Technology Lead Retail Tech Surge Amid SaaS Market Rally
2026-03-04 22:49:45 · Sector: retail · Sentiment: Positive · Impact: 6/10 · Sources: 6

Wix and PAR Technology shares surged on March 4, 2026, signaling a robust appetite for e-commerce and unified commerce infrastructure. The rally, supported by broader gains in the SaaS sector including Cloudflare, highlights a shift toward high-margin digital enablement tools in the retail and restaurant landscapes.
Full story: https://getretailbrief.com/story/wix-par-technology-retail-tech-surge-2026

### Moderna Leads Biotech Rally as Market Sentiment Shifts Toward Growth
2026-03-04 22:18:29 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 5

Moderna (MRNA) shares rose significantly on March 4, 2026, as part of a broader market rally that lifted high-growth technology and clean energy stocks. The move highlights a renewed investor appetite for innovative platforms, signaling a potential recovery for the biotech sector following a period of macro-induced volatility.
Full story: https://getbiobrief.com/story/moderna-growth-stock-rally-march-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.